Results 1 to 10 of about 5,328 (181)

Impact of Long‐Term Structured Exercise on Body Composition in an NTRK Fusion‐Positive NSCLC Patient Treated With Entrectinib [PDF]

Thoracic Cancer
Entrectinib, a first‐generation TRK inhibitor, is effective in NTRK fusion‐positive non‐small cell lung cancer (NSCLC) but commonly induces significant weight gain.
Alice Avancini, Marco Sposito, Gloria Adamoli, Anita Borsati, Christian Ciurnelli, Ilaria Mariangela Scaglione, Serena Eccher, Linda Toniolo, Daniela Tregnago, Lucia Longo, Jessica Insolda, Michele Milella, Federico Schena, Sara Pilotto, Lorenzo Belluomini   +14 more
doaj   +5 more sources

Entrectinib-induced Brugada syndrome leading to ventricular tachycardia in a patient with ROS1 fusion-positive lung adenocarcinoma [PDF]

European Journal of Case Reports in Internal Medicine
A 65-year-old male presented to the emergency room after experiencing syncope while driving, causing a self-inflicted accident. He had previously been diagnosed with stage IV A (cTXN2M1a) lung adenocarcinoma with C-ROS oncogene 1 (ROS1) fusion gene ...
Nobuo Ishiguro, Takeshi Mori, Makito Kaneshiro, Shin Hasegawa, Akimitsu Tanaka, Miyuki Ando, Kazuo Kato   +6 more
doaj   +2 more sources

Entrectinib-Induced Myocarditis and Acute Heart Failure Responding to Steroid Treatment: A Case Report [PDF]

JTO Clinical and Research Reports
A 72-year-old man presented to his general practitioner with worsening dyspnea and was diagnosed with having recurrent ROS1-positive stage IIIB NSCLC 8 years after initial diagnosis and radical treatment for early stage disease.
Mehraab N. Majeed, MBBCh, Subramanian Venkatesan, PhD, Dionysis Papadatos-Pastos, PhD, Tanya Ahmad, MD, Martin Forster, PhD, Polyvios Demetriades, MRCP, Daniel Johnathan Hughes, MRCP, Sarah Benafif, PhD, Siow Ming Lee, FRCP   +8 more
doaj   +3 more sources

Refractory ventricular tachyarrhythmias following entrectinib initiation in metastatic lung adenocarcinoma: a case report [PDF]

Journal of Medical Case Reports
Background Entrectinib is a targeted therapy that has been approved for the treatment of ROS1-positive non-small cell lung cancer. However, this therapy is associated with known but rare cardiotoxic risks.
Lili Tang, Weiwei Wan, Hongtao Zhang, Xiaoyue Li   +3 more
doaj   +2 more sources

Entrectinib can induce nerve cell damage by inhibiting PI3K-AKT and TGF-β signaling pathways [PDF]

Frontiers in Pharmacology
BackgroundThe tyrosine receptor kinase inhibitor (TRKi) entrectinib is used to treat neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumors and ROS1-positive patients.
Qingshan Tang, Jiachen Dong, Feng Zhang, Dan Zhao, Qi Yang, Jiayu Wen, Yuhao Sun, Jifu Wei, Zhixian Liu   +8 more
doaj   +2 more sources

Development of Neuropathic Arthropathy With Entrectinib: Case Report

JTO Clinical and Research Reports, 2022
TRK inhibition can lead to on-target neurologic adverse events. Two cases illustrate the development of neuropathic arthropathy as a side effect of entrectinib.
Nicholas P. Giustini, MD, Hanna Oh, MD, Keith D. Eaton, MD, PhD   +2 more
doaj   +3 more sources

ECMO combined with IABP for the treatment of fulminant myocarditis caused by the targeted drug entrectinib for lung adenocarcinoma: a case report [PDF]

Frontiers in Cardiovascular Medicine
BackgroundEntrectinib, a recently approved multikinase inhibitor indicated for advanced ROS1-positive non-small cell lung cancer (NSCLC), has demonstrated significant survival benefits in metastatic disease.
Qi Yujuan, Qi Yujuan, Ma Xiaozhong, Ma Xiaozhong, Wu Zhenhua, Wu Zhenhua, Bai Yunpeng, Bai Yunpeng   +7 more
doaj   +2 more sources

Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer [PDF]

npj Precision Oncology
Patients treated with RET protein tyrosine kinase inhibitors (TKIs) selpercatinib or pralsetinib develop RET TKI resistance by secondary RET mutations or alterative oncogenes, of which alterative oncogenes pose a greater challenge for disease management ...
Vivek Subbiah, Mohamed A. Gouda, J. Bryan Iorgulescu, Ramona Dadu, Keyur Patel, Steven Sherman, Maria Cabanillas, Mimi Hu, Luz E. Castellanos, Behrang Amini, Funda Meric-Bernstam, Tao Shen, Jie Wu   +12 more
doaj   +3 more sources

Case Report: Therapeutic biopsy guided targeted therapy improves visual acuity and prolongs survival in bilateral uveal metastases as the initial presentation of lung adenocarcinoma [PDF]

Frontiers in Medicine
BackgroundAlthough uveal metastasis is common in lung cancer, reports of bilateral uveal metastasis as the initial symptom in lung adenocarcinoma patients undergoing intraocular biopsy are rare.
Tongtong Ou, Yiliu Yang, Chengda Ren, Fang Lu   +3 more
doaj   +2 more sources

Case Report: A case of first-line treatment for rare ROS1 fusion mutation lung adenocarcinoma with entrectinib [PDF]

Frontiers in Oncology
The incidence of the ROS1 fusion mutation (ROS proto-oncogene 1) in non-small cell lung cancer (NSCLC) is approximately 1-2%. At least 55 partner genes have been identified that can fuse with ROS1.Herein, we report a case of a lung adenocarcinoma patient
Yifan Yang, Yifan Yang, Qing Yi, Wei Yang, Yongzhong Luo, Lemeng Zhang   +5 more
doaj   +2 more sources